INNATE PHARMA

IPH
Real-time Quote. Real-time  - 12/03 11:35:06 am
4.082EUR -6.76%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 273323
Entreprise Value (EV)1 102247
P/E ratio -4,27x-7,00x
Yield --
Capitalization / Revenue 3,88x7,88x
EV / Revenue 1,45x6,03x
EV / EBITDA 2,66x-5,23x
Price to Book 1,75x-8,69x
Nbr of stocks (in thousands) 78 96379 062
Reference price (EUR) 3,464,08
Announcement Date 03/18/2021-
Previous period Next period
1 EUR in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 70,540,9
EBITDA1 38,3-47,2
Operating profit (EBIT)1 -18,5-48,9
Operating Margin -26,3%-119%
Pre-Tax Profit (EBT)1 -64,0-45,5
Net income1 -64,0-46,1
Net margin -90,8%-113%
EPS2 -0,81-0,58
Dividend per Share2 --
Announcement Date 03/18/2021-
Previous period Next period
1 EUR in Million
2 EUR
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 17175,9
Leverage (Debt / EBITDA) -4,48x1,61x
Free Cash Flow1 -52,7-82,0
ROE (Net Profit / Equities) -11,0%-31,8%
Shareholders' equity1 584145
ROA (Net Profit / Asset) --
Assets1 --
Book Value Per Share2 1,97-0,47
Cash Flow per Share2 -0,66-0,69
Capex1 11,310,0
Capex / Sales 16,0%24,4%
Announcement Date 03/18/2021-
Previous period Next period
1 EUR in Million
2 EUR
Financial Ratios
Size 2021e 2022e
Capitalization 323 M € -
Entreprise Value (EV) 247 M € 320 M €
Valuation 2021e 2022e
P/E ratio (Price / EPS) -7,00x -21,1x
Capitalization / Revenue 7,88x 5,84x
EV / Revenue 6,03x 4,46x
EV / EBITDA -5,23x -10,7x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -8,69x -10,2x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -119% -47,8%
Operating Leverage (Delta EBIT / Delta Sales) -3,90x 1,31x
Net Margin (Net Profit / Revenue) -113% -49,2%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) -31,8% -15,6%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   24,4% 147%
Cash Flow / Sales -133% -9,29%
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
Change in Enterprise Value/EBITDA
EPS & Dividend